Related Experiment Video

Updated: Oct 13, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

406

Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications

Toyoshi Yanagihara1,2, Ciaran Scallan3, Kjetil Ask3

  • 1Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Expert Opinion on Therapeutic Targets
|November 17, 2021
PubMed
Abstract

Insights

Idiopathic pulmonary fibrosis (IPF) treatments are advancing, with new drug targets and therapies in early trials offering hope. Precision medicine and biomarkers will guide future treatment strategies for this progressive lung disease.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Translational Medicine

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with significant morbidity and mortality.
  • Current approved therapies can slow IPF progression, but survival remains limited.
  • There is a critical need for novel therapeutic targets and strategies.

Purpose of the Study:

  • To review emerging drug targets and therapies for IPF.
  • To discuss the role of precision medicine and novel technologies in IPF treatment.

Main Methods:

  • Literature review of preclinical and early-stage clinical trials for IPF therapies.
  • Analysis of recent advancements in understanding IPF pathogenesis.
  • Evaluation of novel technologies for guiding therapeutic decisions.

Main Results:

  • Several novel drug targets and therapies are under investigation.
  • Transcriptomics and serum biomarkers show promise for personalized IPF treatment.
  • Combination therapy approaches are being explored.

Conclusions:

  • Despite progress, IPF remains a disease with limited survival, necessitating new therapeutic avenues.
  • Precision medicine, guided by advanced technologies, is crucial for future IPF drug development.
  • Emerging therapies and biomarkers offer potential to improve outcomes for IPF patients.
Keywords:
IPFbiomarkeridiopathic pulmonary fibrosisnovel targetstherapy

More Related Videos

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

435
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

948

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
322
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
275
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
688
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
282